<?xml version="1.0" encoding="UTF-8"?><rss xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title>Pharma-Prime-Economic Times</title><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare</link><description><![CDATA[Pharma News: Read exclusive Pharma and healthcare analysis stories. Latest pharma news, pharmaceutical industry updates, healthcare recent updates and more on ETPrime.]]> </description><language>en-gb</language><lastBuildDate>Thu, 05 Nov 2026 14:18:42 +0530</lastBuildDate><atom:link type="application/rss+xml" rel="self" href="https://economictimes.indiatimes.com/rssfeeds/60187434.cms"/><copyright>Copyright:(C) 2026 Bennett Coleman and Co. Ltd, http://info.indiatimes.com/terms/tou.html</copyright><docs>http://syndication.indiatimes.com/</docs><image><title>Economic Times</title><url>https://img.etimg.com/thumb/msid-76939477,width-600,height-60/economictimes.jpg</url><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare</link></image><item><title><![CDATA[Are patients paying the price for India’s PE-led healthcare boom?]]> </title><description><![CDATA[In just about three years, nearly 60 hospital-linked PE deals have been signed for eye-popping values of INR49,000 crore.]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/are-patients-paying-the-price-for-indias-pe-led-healthcare-boom/primearticleshow/133304885.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-133304885,imgsize-1477785.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/are-patients-paying-the-price-for-indias-pe-led-healthcare-boom/primearticleshow/133304885.cms</guid><pubDate>Tue, 18 Aug 2026 04:00:00 +0530</pubDate></item><item><title><![CDATA[How this man proved M&amp;As need not be disasters even if tough]]> </title><description><![CDATA[The deal to acquire Organon for a record USD11.75 billion catapults Sun Pharma into the big league of top 25 pharmaceutical companies globally. But there are reasons why Sun Pharma chairman Dilip Shanghvi is happy, excited and a little bit anxious at the same time.]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/how-this-man-proved-mas-need-not-be-disasters-even-if-tough/primearticleshow/130793183.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-130793183,imgsize-769411.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/how-this-man-proved-mas-need-not-be-disasters-even-if-tough/primearticleshow/130793183.cms</guid><pubDate>Tue, 05 May 2026 04:00:00 +0530</pubDate></item><item><title><![CDATA[German giant Bayer to push harder on tiered pricing for its drugs]]> </title><description><![CDATA[In an exclusive interview, Stefan Oelrich, Bayer’s global head of pharmaceuticals business, talked about a range of issues including the pharma major’s tailormade India portfolio, investment in innovation, and much more.]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/german-giant-bayer-to-push-harder-on-tiered-pricing-for-its-drugs/primearticleshow/125101725.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-125101725,imgsize-43892.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/german-giant-bayer-to-push-harder-on-tiered-pricing-for-its-drugs/primearticleshow/125101725.cms</guid><pubDate>Wed, 05 Nov 2025 11:00:00 +0530</pubDate></item><item><title><![CDATA[From near bankruptcy to blockbuster drug: How Khorakiwala turned around Wockhardt]]> </title><description><![CDATA[Wockhardt’s Habil Khorakiwala has seen the most harrowing days. From a payment default to bond holders to troubled factories, Khorakiwala pulled the company out of its biggest crises. Now, just one drug, that is touted as the biggest breakthrough in antibiotics after penicillin, can bring him back in the reckoning. ]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/from-near-bankruptcy-to-blockbuster-drug-how-khorakiwala-turned-around-wockhardt/primearticleshow/122795920.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-122795920,imgsize-25102.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/from-near-bankruptcy-to-blockbuster-drug-how-khorakiwala-turned-around-wockhardt/primearticleshow/122795920.cms</guid><pubDate>Mon, 21 Jul 2025 04:00:00 +0530</pubDate></item><item><title><![CDATA[Ozempic, Wegovy, Mounjaro: Are GLP-1 drugs weight loss wonders or health gamble?]]> </title><description><![CDATA[With India’s rising burden of diabetes and obesity, GLP-1 drugs may play a growing role in treatment. But the excitement must be matched by realistic expectations, robust safety monitoring, and clear clinical guidelines.]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/ozempic-wegovy-mounjaro-are-glp-1-drugs-weight-loss-wonders-or-health-gamble/primearticleshow/122189485.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-122189485,imgsize-44178.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/ozempic-wegovy-mounjaro-are-glp-1-drugs-weight-loss-wonders-or-health-gamble/primearticleshow/122189485.cms</guid><pubDate>Wed, 02 Jul 2025 04:55:00 +0530</pubDate></item><item><title><![CDATA[As Novo Nordisk scales back, Eris and Biocon Biologics hit the sweet spot in India’s insulin market]]> </title><description><![CDATA[A partial phase out of a top insulin product by Danish drug maker Novo Nordisk may open a bounty for Eris Pharma and its manufacturing partner Biocon Biologics.]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/as-novo-nordisk-scales-back-eris-and-biocon-biologics-hit-the-sweet-spot-in-indias-insulin-market/primearticleshow/120697277.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-120697277,imgsize-130800.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/as-novo-nordisk-scales-back-eris-and-biocon-biologics-hit-the-sweet-spot-in-indias-insulin-market/primearticleshow/120697277.cms</guid><pubDate>Tue, 29 Apr 2025 04:55:00 +0530</pubDate></item><item><title><![CDATA[India has a major health insurance headache]]> </title><description><![CDATA[It is important for state-run health insurance to ensure more hospitals join to provide a safety net to the poor.]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/india-has-a-major-health-insurance-headache/primearticleshow/119854990.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-119854990,imgsize-24096.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/india-has-a-major-health-insurance-headache/primearticleshow/119854990.cms</guid><pubDate>Tue, 01 Apr 2025 13:43:01 +0530</pubDate></item><item><title><![CDATA[How a genome map can help India fight cancer better]]> </title><description><![CDATA[Genetic structure could hold some answers to the vexed issue of cancer. A reference set of genetic variants, specific to India’s diverse ethnic groups, can improve disease modelling and treatment. ]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/how-a-genome-map-can-help-india-fight-cancer-better/primearticleshow/118394852.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-118394852,imgsize-118956.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/how-a-genome-map-can-help-india-fight-cancer-better/primearticleshow/118394852.cms</guid><pubDate>Thu, 20 Feb 2025 06:00:00 +0530</pubDate></item><item><title><![CDATA[What’s making GBS nerve disorder go viral in Pune]]> </title><description><![CDATA[Guillain-Barré Syndrome is a rare nerve disorder. It is not a communicable disease. Why is it spreading like a viral outbreak? ]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/whats-making-gbs-nerve-disorder-go-viral-in-pune/primearticleshow/117623998.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-117623998,imgsize-30162.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/whats-making-gbs-nerve-disorder-go-viral-in-pune/primearticleshow/117623998.cms</guid><pubDate>Tue, 28 Jan 2025 13:33:15 +0530</pubDate></item><item><title><![CDATA[This Ichnos Glenmark drug promises to BEAT cancer, affordably. Can it challenge Big Pharma?]]> </title><description><![CDATA[The drug has given promising results for the treatment of multiple myeloma, a rare form of blood cancer. The market for such drugs is expected to touch USD30 billion by the end of the decade. Although these are early days, can it take on the likes of J&amp;J, Gilead, and Sanofi?  ]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/this-ichnos-glenmark-drug-promises-to-beat-cancer-affordably-can-it-challenge-big-pharma/primearticleshow/117379623.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-117379623,imgsize-54812.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/this-ichnos-glenmark-drug-promises-to-beat-cancer-affordably-can-it-challenge-big-pharma/primearticleshow/117379623.cms</guid><pubDate>Mon, 20 Jan 2025 05:55:00 +0530</pubDate></item><item><title><![CDATA[Can Cipla win over diabetes patients with a painless, inhalable insulin?]]> </title><description><![CDATA[Cipla is taking a bold decision to sell Afrezza, an insulin that can be inhaled from the mouth. Will it succeed in breaking into the stronghold of global insulin makers that sell injectable insulins for diabetes patients?]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/can-cipla-make-inhaled-insulin-a-successful-option-for-diabetes-patients/primearticleshow/116362903.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-116362903,imgsize-17006.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/can-cipla-make-inhaled-insulin-a-successful-option-for-diabetes-patients/primearticleshow/116362903.cms</guid><pubDate>Mon, 16 Dec 2024 14:25:28 +0530</pubDate></item><item><title><![CDATA[Where are PE players profiting in the healthcare sector?]]> </title><description><![CDATA[Private equity investors have been investing large sums of money in hospitals. Certain types of hospital chains are delivering healthy returns for such investors. ]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/pe-firms-in-pink-of-health-on-improving-returns-from-hospital-investments-/primearticleshow/116002377.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-116002377,imgsize-91376.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/pe-firms-in-pink-of-health-on-improving-returns-from-hospital-investments-/primearticleshow/116002377.cms</guid><pubDate>Thu, 05 Dec 2024 14:51:12 +0530</pubDate></item><item><title><![CDATA[Can herbs, starvation cure cancer? Sidhu flicks row, gets caught by Twitterati]]> </title><description><![CDATA[Navjot Singh Sidhu claimed his wife’s advanced-stage cancer was cured through alternative remedies, sparking controversy. His suggestion that fasting could kill cancer cells drew criticism. To address this, ET Prime spoke to experts who warned against such misconceptions. ]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/can-herbs-starvation-cure-cancer-sidhu-flicks-row-gets-caught-by-twitterati/primearticleshow/115689444.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-115689444,imgsize-55876.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/can-herbs-starvation-cure-cancer-sidhu-flicks-row-gets-caught-by-twitterati/primearticleshow/115689444.cms</guid><pubDate>Tue, 26 Nov 2024 14:03:04 +0530</pubDate></item><item><title><![CDATA[These bugs are killing 5 million every year, yet doctors have few options to fight them]]> </title><description><![CDATA[Doctors are grappling with a raft of unsparing hospital-acquired superbugs broadly known as anti-microbial resistance or AMR. Are bacterial infections the next big lethal adversary for mankind? ]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/these-bugs-are-killing-5-million-every-year-yet-doctors-have-few-options-to-fight-them/primearticleshow/115393232.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-115393232,imgsize-89874.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/these-bugs-are-killing-5-million-every-year-yet-doctors-have-few-options-to-fight-them/primearticleshow/115393232.cms</guid><pubDate>Mon, 18 Nov 2024 05:55:00 +0530</pubDate></item><item><title><![CDATA[What the headlong fall of 23andMe signals for India’s genetic-testing market]]> </title><description><![CDATA[23andMe, a pioneer in genetic testing, struggles to maintain its early success. As quickly as it soared, its market value plummeted, leaving the company’s future uncertain. ET Prime examines the challenges faced by 23andMe, along with opportunities and potential implications for India’s genetic-testing market. ]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/what-the-headlong-fall-of-23andme-signals-for-indias-genetic-testing-market/primearticleshow/115328045.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-115328045,imgsize-134224.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/what-the-headlong-fall-of-23andme-signals-for-indias-genetic-testing-market/primearticleshow/115328045.cms</guid><pubDate>Fri, 15 Nov 2024 13:09:25 +0530</pubDate></item><item><title><![CDATA[How fake drugs, Jan Aushadhi push are eating away the profits of top pharma companies]]> </title><description><![CDATA[Is the pharma market, which is currently at INR2.17 lakh crore (USD25.8 billion), getting too crowded? While some industry experts believe a few clear signs of fatigue have emerged, many say it is not a doom scenario yet and a rebound may not be far. ]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/how-fake-drugs-jan-aushadhi-push-are-eating-away-the-profits-of-top-pharma-companies/primearticleshow/114426602.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-114426602,imgsize-1448085.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/how-fake-drugs-jan-aushadhi-push-are-eating-away-the-profits-of-top-pharma-companies/primearticleshow/114426602.cms</guid><pubDate>Tue, 22 Oct 2024 05:55:00 +0530</pubDate></item><item><title><![CDATA[The dark reality of melatonin behind India’s USD289 million wild chase for good sleep]]> </title><description><![CDATA[Most Indians are sleep-deprived and are turning to melatonin for a better night’s rest. The global melatonin market reached USD2.15 billion in 2022, and India’s sleep aid market is projected to generate USD289 million in revenue in 2024 alone. While melatonin is often considered harmless, everything has a flipside.  ]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/the-dark-reality-of-melatonin-behind-indias-usd289-million-wild-chase-for-good-sleep/primearticleshow/114324133.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-114324133,imgsize-15170.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/the-dark-reality-of-melatonin-behind-indias-usd289-million-wild-chase-for-good-sleep/primearticleshow/114324133.cms</guid><pubDate>Fri, 18 Oct 2024 05:55:00 +0530</pubDate></item><item><title><![CDATA[Sun Pharma, Torrent, Alkem under lens for inferior medicines. It points to a leaky supply chain.]]> </title><description><![CDATA[In the crosshairs of the latest controversy on whether a drug is spurious or “not of standard quality” is the Indian patient. The pharma industry suffered a body blow recently after government agencies pulled up over 50 popular medicine brands. How do patients trust their medicines? ]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/sun-pharma-torrent-alkem-under-lens-for-inferior-medicines-it-points-to-a-leaky-supply-chain-/primearticleshow/113918170.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-113918170,imgsize-1089229.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/sun-pharma-torrent-alkem-under-lens-for-inferior-medicines-it-points-to-a-leaky-supply-chain-/primearticleshow/113918170.cms</guid><pubDate>Fri, 04 Oct 2024 05:55:00 +0530</pubDate></item><item><title><![CDATA[Affordability is critical when it comes to patient care: GE HealthCare’s Sarawate]]> </title><description><![CDATA[GE HealthCare is riding high on the India opportunity. Speaking exclusively to ET Prime, Chaitanya Sarawate, president and CEO of GE HealthCare South Asia and managing director of Wipro GE Healthcare, discusses why the magic is in building localised products.   ]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/affordability-is-critical-when-it-comes-to-patient-care-ge-healthcares-sarawate/primearticleshow/113469679.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-113469679,imgsize-41448.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/affordability-is-critical-when-it-comes-to-patient-care-ge-healthcares-sarawate/primearticleshow/113469679.cms</guid><pubDate>Thu, 19 Sep 2024 04:15:00 +0530</pubDate></item><item><title><![CDATA[How rising awareness about infertility is making IVF a USD4.6 billion opportunity]]> </title><description><![CDATA[IVF has become a beacon of hope for many couples. The Indian fertility market has witnessed a remarkable 20% growth. As per current estimates, India conducts an average of 2 lakh-2.5 lakh IVF cycles per year.  ]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/how-raising-awareness-about-infertility-is-making-ivf-a-usd4-6-billion-opportunity/primearticleshow/113065605.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-113065605,imgsize-25284.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/how-raising-awareness-about-infertility-is-making-ivf-a-usd4-6-billion-opportunity/primearticleshow/113065605.cms</guid><pubDate>Thu, 05 Sep 2024 13:53:12 +0530</pubDate></item><item><title><![CDATA[Mpox virus is back. Is vaccine maker Serum Institute ready?]]> </title><description><![CDATA[A mutated mpox virus that started from Africa has now reached Europe and closer home to Pakistan. While it’s too early to gauge the threat of a potential pandemic, India must prioritise its own vaccine and prepare for possible outbreaks. ]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/mpox-virus-is-back-are-indias-vaccine-makers-serum-institute-bharat-biotech-ready/primearticleshow/112623044.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-112623044,imgsize-1008133.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/mpox-virus-is-back-are-indias-vaccine-makers-serum-institute-bharat-biotech-ready/primearticleshow/112623044.cms</guid><pubDate>Mon, 19 Aug 2024 13:00:00 +0530</pubDate></item><item><title><![CDATA[India must protect doctors. They are scarce, and it takes years to train one.]]> </title><description><![CDATA[The tragic case in Kolkata’s RG Kar Medical College once again exposed the deep flaws in India’s healthcare system. While there are established guidelines and mechanisms to guarantee safety to the medical staff, the ground reality is often different.  ]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/india-must-protect-doctors-they-are-scarce-and-it-takes-years-to-train-one-/primearticleshow/112562632.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-112562632,imgsize-1574525.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/india-must-protect-doctors-they-are-scarce-and-it-takes-years-to-train-one-/primearticleshow/112562632.cms</guid><pubDate>Fri, 16 Aug 2024 13:42:38 +0530</pubDate></item><item><title><![CDATA[Sun Pharma’s new drug to take on Pfizer, Eli Lilly is having a bad hair day.]]> </title><description><![CDATA[Last year, Sun Pharma infused over INR4,688 crore to buy US-based Concert Pharma. That deal gave it rights to a drug that helps hair growth in patients suffering from alopecia areata. Leqselvi, the drug, now has the US FDA approval. But there is a new twist in the tale.]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/sun-pharmas-new-drug-to-take-on-pfizer-eli-lilly-is-having-a-bad-hair-day-/primearticleshow/112270316.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-112270316,imgsize-46884.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/sun-pharmas-new-drug-to-take-on-pfizer-eli-lilly-is-having-a-bad-hair-day-/primearticleshow/112270316.cms</guid><pubDate>Mon, 05 Aug 2024 04:15:00 +0530</pubDate></item><item><title><![CDATA[Why leading doctors and scientists pin hope on green jackfruit to fight fatty liver and cancer]]> </title><description><![CDATA[A recent animal study has proven green jackfruit flour’s potency in treating fatty liver and liver cancer. An expert group of doctors, scientists and researchers are coming together to initiate an elaborate clinical trial on this.  ]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/why-leading-doctors-scientists-pin-hope-on-green-jackfruit-to-fight-fatty-liver-and-cancer/primearticleshow/111615313.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-111615313,imgsize-143586.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/why-leading-doctors-scientists-pin-hope-on-green-jackfruit-to-fight-fatty-liver-and-cancer/primearticleshow/111615313.cms</guid><pubDate>Wed, 10 Jul 2024 04:00:00 +0530</pubDate></item><item><title><![CDATA[This Ranjan Pai investment opens the door to a USD30 billion opportunity]]> </title><description><![CDATA[Ranjan Pai is among India’s most influential investors. So, when he makes a move into senior care, it is time to sit up and take notice of the sector, not to mention the broader grey economy. ]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/this-ranjan-pai-investment-opens-the-door-to-a-usd30-billion-opportunity/primearticleshow/111293277.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-111293277,imgsize-30552.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/this-ranjan-pai-investment-opens-the-door-to-a-usd30-billion-opportunity/primearticleshow/111293277.cms</guid><pubDate>Thu, 27 Jun 2024 04:15:00 +0530</pubDate></item><item><title><![CDATA[What an Indian pharma giant’s new drug find can gain the world’s obesity fight]]> </title><description><![CDATA[Selling weight-loss drugs is an opportunity no pharma company wants to miss. Now a leading drug maker from India joins this bandwagon.]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/what-an-indian-pharma-giants-new-drug-find-can-gain-the-worlds-obesity-fight/primearticleshow/111267350.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-111267350,imgsize-46360.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/what-an-indian-pharma-giants-new-drug-find-can-gain-the-worlds-obesity-fight/primearticleshow/111267350.cms</guid><pubDate>Wed, 26 Jun 2024 04:00:00 +0530</pubDate></item><item><title><![CDATA[This is the lady responsible for helping improve USD50 billion Indian pharma’s quality]]> </title><description><![CDATA[In the past, many within the Indian pharma industry looked at US FDA audits as motivated and a larger conspiracy against it. But this senior official, who heads the Indian operations of the US FDA, and will soon move to China, worked with Indian pharma companies to slowly change that, and bring in a culture of quality in the industry.]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/sarah-mcmullen-the-us-fda-exec-who-soothed-indian-pharmas-frayed-nerves/primearticleshow/111240837.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-111240837,imgsize-27038.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/sarah-mcmullen-the-us-fda-exec-who-soothed-indian-pharmas-frayed-nerves/primearticleshow/111240837.cms</guid><pubDate>Tue, 25 Jun 2024 04:15:00 +0530</pubDate></item><item><title><![CDATA[What lured Mankind to this low-profile, niche pharma company]]> </title><description><![CDATA[Advent controlled-BSV has charted an exceptional turnaround over the last five years, seeing a 3x jump in its valuation. Its specialised products in women’s health and a robust research pipeline makes it a cynosure of all eyes. As Mankind announces acquisition of BSV in a USD1.6 billion deal, ET Prime explains the company’s journey and its outlook.  ]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/why-mankind-dr-reddys-and-pe-firms-are-so-interested-in-low-profile-bsv/primearticleshow/111064903.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-111064903,imgsize-290582.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/why-mankind-dr-reddys-and-pe-firms-are-so-interested-in-low-profile-bsv/primearticleshow/111064903.cms</guid><pubDate>Tue, 18 Jun 2024 04:00:00 +0530</pubDate></item><item><title><![CDATA[Cracking DaVinci: How this Indian doctor’s Mantra is revolutionising robotic surgeries]]> </title><description><![CDATA[In an exclusive interaction with ET Prime, cardiac surgeon Sudhir Prem Srivastava, the man behind 1,500 successful robotic surgeries, discusses his eventful journey. He details the concept, design and instrumentation of five-armed Mantra, the robotic surgery system, and the dire need to make such products available at lower costs.]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/cracking-davinci-how-this-indian-doctors-mantra-is-revolutionising-robotic-surgeries/primearticleshow/110774095.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-110774095,imgsize-1605436.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/cracking-davinci-how-this-indian-doctors-mantra-is-revolutionising-robotic-surgeries/primearticleshow/110774095.cms</guid><pubDate>Fri, 07 Jun 2024 04:15:00 +0530</pubDate></item><item><title><![CDATA[Say cheese! A drug to regrow teeth is in clinical trials]]> </title><description><![CDATA[Japanese researchers are soon embarking on human clinical trials for a medicine that will help regrow teeth.]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/say-cheese-a-drug-to-regrow-teeth-is-in-clinical-trials/primearticleshow/110669331.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-110669331,imgsize-634983.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/say-cheese-a-drug-to-regrow-teeth-is-in-clinical-trials/primearticleshow/110669331.cms</guid><pubDate>Mon, 03 Jun 2024 17:44:54 +0530</pubDate></item><item><title><![CDATA[How a 2012 bet supercharged Sun Pharma]]> </title><description><![CDATA[Sun Pharma has been having a great run for the past one year in the stock market. A big bet it made in 2012 has a lot to do with its positive run.]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/how-a-2012-bet-supercharged-sun-pharma/primearticleshow/110402394.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-110402394,imgsize-134984.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/how-a-2012-bet-supercharged-sun-pharma/primearticleshow/110402394.cms</guid><pubDate>Fri, 24 May 2024 19:05:27 +0530</pubDate></item><item><title><![CDATA[For scientific breakthroughs, India needs its own J-Labs…or lose the race]]> </title><description><![CDATA[Something as cool as a J-Labs can be a welcome step. From fear of failing, scientists can look at the opportunities of scaling. On its part, the government had proposed an innovation-linked fund for new research ideas. But that may have a limited impact.]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/for-scientific-breakthroughs-india-needs-its-own-j-labsor-lose-the-race/primearticleshow/110278634.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-110278634,imgsize-82170.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/for-scientific-breakthroughs-india-needs-its-own-j-labsor-lose-the-race/primearticleshow/110278634.cms</guid><pubDate>Tue, 21 May 2024 04:30:00 +0530</pubDate></item><item><title><![CDATA[Tipsy tinctures, a legal loophole and a brave excise official's lonely fight]]> </title><description><![CDATA[A well-oiled syndicate of producers, wholesalers and retailers operating across several districts in UP, Bihar and other northern states had exploited a loophole in the 80-year-old law to sell cardamom-laced tinctures as ‘disguised liquor’. But that is about to change.]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/narcos-north-india-how-a-vigilant-excise-inspector-triggered-a-law-change-to-end-tipsy-tinctures/primearticleshow/109862801.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-109862801,imgsize-48398.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/narcos-north-india-how-a-vigilant-excise-inspector-triggered-a-law-change-to-end-tipsy-tinctures/primearticleshow/109862801.cms</guid><pubDate>Mon, 06 May 2024 04:00:00 +0530</pubDate></item><item><title><![CDATA[Prostate cancer: what the blue ribbon needs to unlearn from the pink ribbon]]> </title><description><![CDATA[As per a recent report in The Lancet, the incidence of prostate cancer is expected to double in India over the next few years. A crucial weapon in averting a severe health catastrophe will be early detection. But before addressing the issue of testing, there’s a knotty ribbon problem to be solved. ]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/prostate-cancer-what-the-blue-ribbon-needs-to-unlearn-from-its-pink-counterpart/primearticleshow/109862746.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-109862746,imgsize-10644.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/prostate-cancer-what-the-blue-ribbon-needs-to-unlearn-from-its-pink-counterpart/primearticleshow/109862746.cms</guid><pubDate>Mon, 06 May 2024 00:02:00 +0530</pubDate></item><item><title><![CDATA[Decades late, these set of basic rules for Indian pharma can save lives]]> </title><description><![CDATA[The government is finally addressing the need for basic rules around pharma recalls.   ]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/decades-late-these-set-of-basic-rules-for-indian-pharma-can-save-lives/primearticleshow/109752623.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-109752623,imgsize-264098.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/decades-late-these-set-of-basic-rules-for-indian-pharma-can-save-lives/primearticleshow/109752623.cms</guid><pubDate>Wed, 01 May 2024 15:17:35 +0530</pubDate></item><item><title><![CDATA[How this Advent PE-backed Indian firm is prepping to take on Chinese big pharma]]> </title><description><![CDATA[Advent, which merged Suven Pharma with Cohance Lifesciences in February, looks to take advantage of the China+1 wave and other geopolitical tailwinds. While the skills of its scientists give India an edge in pharma outsourcing, the scale of local contract manufacturers pales in front of global rivals from China and Europe. Can Advent change this narrative?]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/how-this-advent-pe-backed-indian-firm-is-prepping-to-take-on-chinese-big-pharma/primearticleshow/109355238.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-109355238,imgsize-83870.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/how-this-advent-pe-backed-indian-firm-is-prepping-to-take-on-chinese-big-pharma/primearticleshow/109355238.cms</guid><pubDate>Wed, 17 Apr 2024 04:15:00 +0530</pubDate></item><item><title><![CDATA[How this Indian state is showing the way to treat cancer patients]]> </title><description><![CDATA[With an alarming rise in cancer diagnosis rate in India, especially among the younger cohort, timely screening and therapeutic intervention are the need of the hour. One small state has devised a unique health model for cancer management and success. Here’s how it can help ensure an improved disease-free survival.]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/how-this-indian-state-is-showing-the-way-to-treat-cancer-patients/primearticleshow/109170384.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-109170384,imgsize-55406.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/how-this-indian-state-is-showing-the-way-to-treat-cancer-patients/primearticleshow/109170384.cms</guid><pubDate>Wed, 10 Apr 2024 04:30:00 +0530</pubDate></item><item><title><![CDATA[Many new mothers face this problem that plucks the joy out of giving birth.]]> </title><description><![CDATA[An overlooked mental health challenge faced by new mothers. A powerful new drug Zurzuvae could be critical in fighting back. It should have been an obvious match. Yet things may not turn out that way because of pharma industry’s pricing vagaries as well as the lack of conversation around the condition itself. ]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/many-new-mothers-face-this-problem-that-plucks-the-joy-out-of-giving-birth-/primearticleshow/109112246.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-109112246,imgsize-18652.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/many-new-mothers-face-this-problem-that-plucks-the-joy-out-of-giving-birth-/primearticleshow/109112246.cms</guid><pubDate>Mon, 08 Apr 2024 00:04:12 +0530</pubDate></item><item><title><![CDATA[No free gifts to doctors, but latest government diktat is still not effective]]> </title><description><![CDATA[The new government notice tries to prevent the pharmaceutical companies from inducing doctors to prescribe their medicines through vacations, gifts, and free educational material. It is unlikely to succeed.]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/no-free-gifts-to-doctors-but-ucpmp-is-not-effective/primearticleshow/108571283.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-108571283,imgsize-20606.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/no-free-gifts-to-doctors-but-ucpmp-is-not-effective/primearticleshow/108571283.cms</guid><pubDate>Mon, 18 Mar 2024 05:14:58 +0530</pubDate></item><item><title><![CDATA[Remembering Novartis’ Ranjit Shahani: The pharma titan who walked a tightrope for India]]> </title><description><![CDATA[Ranjit Shahani will be remembered for his astute leadership and trademark calmness amid chaos. As chief of Novartis in India for nearly two decades, his tenure coincided with unprecedented challenges. Shahani had the tedious task of defending his company from a vexing patent battle while convincing the leadership to look at India’s brighter side. He balanced both with élan.]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/remembering-novartis-ranjit-shahani-the-pharma-titan-who-walked-a-tightrope-for-india/primearticleshow/108372955.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-108372955,imgsize-28856.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/remembering-novartis-ranjit-shahani-the-pharma-titan-who-walked-a-tightrope-for-india/primearticleshow/108372955.cms</guid><pubDate>Mon, 11 Mar 2024 04:30:00 +0530</pubDate></item><item><title><![CDATA[Kotdwar to Hyderabad: How a fake-drugs racket in Uttarakhand with roots in south India was busted.]]> </title><description><![CDATA[In a rare breakthrough, the Telangana drug administration has unearthed a well-oiled network of spurious drug peddlers with operations spanning from the northern state of India to the narrow alleys of Hyderabad. According to senior police officers, it’s just the tip of an iceberg.]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/kotdwar-to-hyderabad-how-a-fake-drugs-racket-in-uttarakhand-with-roots-in-south-india-was-busted-/primearticleshow/108241441.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-108241441,imgsize-71510.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/kotdwar-to-hyderabad-how-a-fake-drugs-racket-in-uttarakhand-with-roots-in-south-india-was-busted-/primearticleshow/108241441.cms</guid><pubDate>Wed, 06 Mar 2024 04:30:00 +0530</pubDate></item><item><title><![CDATA[India has an incredibly rich talent pool in pharma, says Bristol Myers CEO Chris Boerner]]> </title><description><![CDATA[“We are building to be one of the fastest-growing companies by the end of the decade,” says Chris Boerner, CEO, Bristol Myers Squibb. In an exclusive interaction with ET Prime, Boerner discusses the company’s focus on AI and its transformational impact on medicines, and their growing presence in India.]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/ai-can-bring-transformational-medicines-india-has-incredible-talent-pool-bristol-myers-ceo/primearticleshow/108183810.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-108183810,imgsize-40830.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/ai-can-bring-transformational-medicines-india-has-incredible-talent-pool-bristol-myers-ceo/primearticleshow/108183810.cms</guid><pubDate>Mon, 04 Mar 2024 04:00:00 +0530</pubDate></item><item><title><![CDATA[Chronic Lyme and other pathogens: Tackling long-haul diseases.]]> </title><description><![CDATA[As long-haul infections continue to surge, and climate change pushes ticks into new habitats, finding out the causes of these conditions and coming up with cures will become ever more essential.]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/chronic-lyme-and-other-pathogens-tackling-long-haul-diseases-/primearticleshow/108115638.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-108115638,imgsize-53716.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/chronic-lyme-and-other-pathogens-tackling-long-haul-diseases-/primearticleshow/108115638.cms</guid><pubDate>Fri, 01 Mar 2024 04:30:00 +0530</pubDate></item><item><title><![CDATA[Once dumped by investors, Orchid Pharma blooms in glory with first novel antibiotic drug]]> </title><description><![CDATA[Orchid Pharma had outlicensed its experimental antibiotic drug to Allecra Therapeutics of Germany. After years of research that drug has won crucial approvals from the US FDA and European drug regulatory agency. This marks an important milestone. The drug, invented by Indian scientists in 2008, takes a big leap in the global war against bacterial infections.]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/once-dumped-by-investors-orchid-pharma-blooms-in-glory-with-first-novel-antibiotic-drug/primearticleshow/108048014.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-108048014,imgsize-36284.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/once-dumped-by-investors-orchid-pharma-blooms-in-glory-with-first-novel-antibiotic-drug/primearticleshow/108048014.cms</guid><pubDate>Wed, 28 Feb 2024 04:15:00 +0530</pubDate></item><item><title><![CDATA[A new lease of life: How India’s first CAR-T cell therapy is helping patients battle cancer.]]> </title><description><![CDATA[NexCAR 19, India’s first cell therapy to treat a specific form of blood cancer, is showing encouraging results. Now listed at 40 hospitals across the country, its indigenous maker, ImmunoACT, is driving a medical revolution. Can the battle against the emperor of all maladies be won?]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/a-new-lease-of-life-how-indias-first-car-t-cell-therapy-is-helping-patients-battle-cancer-/primearticleshow/107865438.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-107865438,imgsize-45356.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/a-new-lease-of-life-how-indias-first-car-t-cell-therapy-is-helping-patients-battle-cancer-/primearticleshow/107865438.cms</guid><pubDate>Wed, 21 Feb 2024 06:41:05 +0530</pubDate></item><item><title><![CDATA[An army of 12,000 medical reps: How Rajeev Juneja flexed Mankind to the pharma top order]]> </title><description><![CDATA[While Ramesh Juneja has led Mankind Pharma for three decades, his brother Rajeev kept in tow and took charge of key operations. Suave and yet rustic, the younger Juneja has a unique style to push the 12,000-strong team of medical representatives in a fiercely competitive market and can sense the pulse of his people toiling hard.]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/an-army-of-12000-medical-reps-how-rajeev-juneja-flexed-mankind-to-the-pharma-top-order/primearticleshow/107835166.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-107835166,imgsize-39948.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/an-army-of-12000-medical-reps-how-rajeev-juneja-flexed-mankind-to-the-pharma-top-order/primearticleshow/107835166.cms</guid><pubDate>Tue, 20 Feb 2024 06:44:08 +0530</pubDate></item><item><title><![CDATA[Ka-Ching: Global drug makers ride luck in pursuit of blockbuster drugs, vaccines]]> </title><description><![CDATA[The successes of top pharmaceutical products of late show that drug companies have been plain lucky to hit it big. While long-term strategies continue to be key, drug makers have often struck gold with pipeline compounds that they had once simply dumped.]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/ka-ching-how-global-drug-makers-are-riding-on-luck-in-their-pursuit-of-blockbuster-drugs-vaccines/primearticleshow/107697591.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-107697591,imgsize-107944.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/ka-ching-how-global-drug-makers-are-riding-on-luck-in-their-pursuit-of-blockbuster-drugs-vaccines/primearticleshow/107697591.cms</guid><pubDate>Thu, 15 Feb 2024 03:00:00 +0530</pubDate></item><item><title><![CDATA[We do a few things, but those few things must be the best in the world: Novo Nordisk’s top exec]]> </title><description><![CDATA[Novo Nordisk, the most valuable pharmaceutical company in the world, turned 100 last year. While it is largely known for its insulins, its anti-obesity drugs are making waves of late. Maziar Mike Doustdar, executive vice-president, international operations at Novo Nordisk tells ET Prime the beliefs that distinguish the company.]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/we-do-a-few-things-but-those-few-things-must-be-the-best-in-the-world-novo-nordisks-top-exec/primearticleshow/107210071.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-107210071,imgsize-48412.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/we-do-a-few-things-but-those-few-things-must-be-the-best-in-the-world-novo-nordisks-top-exec/primearticleshow/107210071.cms</guid><pubDate>Mon, 29 Jan 2024 04:30:00 +0530</pubDate></item><item><title><![CDATA[Fixing India’s broken healthcare infra at the bottom, Ujala Cygnus is a rare example]]> </title><description><![CDATA[India’s smaller cities and hinterland remain a neglected lot even as five-star specialty hospitals flourish in the metros. To have its healthcare parameters on track, India needs an urgent flow of investments in tertiary-care hospitals in tier-II and tier-III cities. But building and managing tertiary-care hospitals isn’t easy. Examples like Ujala Cygnus can show the way forward. ]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/fixing-indias-broken-healthcare-infra-at-the-bottom-ujala-cygnus-is-a-rare-example/primearticleshow/107054000.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-107054000,imgsize-54914.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/fixing-indias-broken-healthcare-infra-at-the-bottom-ujala-cygnus-is-a-rare-example/primearticleshow/107054000.cms</guid><pubDate>Tue, 23 Jan 2024 04:15:00 +0530</pubDate></item><item><title><![CDATA[From ‘facilitator’ to ‘regulator’: How Rajeev Raghuvanshi is fixing the gaps in pharma industry]]> </title><description><![CDATA[The pharmaceutical industry, and the central drug regulatory agency, faced a severe reputation crisis following the deaths of 70 children in Gambia due to contaminated cough syrups in 2022. A few months later, Rajeev Raghuvanshi took over as the Drug Controller General of India and is currently driving a transformational change. Can he set a high bar for product quality? ]]> </description><link>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/from-facilitator-to-regulator-how-rajeev-raghuvanshi-is-fixing-the-gaps-in-pharma-industry/primearticleshow/106644877.cms</link><enclosure type="image/jpeg" url="https://img.etimg.com/photo/msid-106644877,imgsize-54868.cms" length="0"/><guid>https://economictimes.indiatimes.com/prime/pharma-and-healthcare/from-facilitator-to-regulator-how-rajeev-raghuvanshi-is-fixing-the-gaps-in-pharma-industry/primearticleshow/106644877.cms</guid><pubDate>Tue, 09 Jan 2024 04:00:00 +0530</pubDate></item></channel></rss>